Does Rallies show 13F holders for HYPR?

Yes. Rallies tracks hedge fund and 13F ownership data for HYPR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is HYPR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HYPR. It does not provide personalized investment advice.

HYPR (Hyperfine, Inc. Class A Common Stock) Stock Analysis - Hedge Fund Holdings

Hyperfine, Inc. Class A Common Stock (HYPR) is a publicly traded Healthcare sector company. As of May 21, 2026, HYPR trades at $1.49 with a market cap of $143.94M and a P/E ratio of -3.66. HYPR moved +5.67% today. Year to date, HYPR is +49.49%; over the trailing twelve months it is +137.83%. Its 52-week range spans $0.53 to $2.22. Analyst consensus is strong buy with an average price target of $2.17. Rallies surfaces HYPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns HYPR stock?

Hedge funds tracked by Rallies that own HYPR include Highbridge Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Hyperfine, Inc. Class A Common Stock.

HYPR Key Metrics

Key financial metrics for HYPR
Metric	Value
Price	$1.49
Market Cap	$143.94M
P/E Ratio	-3.66
EPS	$-0.40
Dividend Yield	0.00%
52-Week High	$2.22
52-Week Low	$0.53
Volume	50
Avg Volume	0
Revenue (TTM)	$15.33M
Net Income	$-34.78M
Gross Margin	51.20%

Top Hedge Funds Holding HYPR

Highbridge Capital holds 100 shares of HYPR, changed +0.00% as of Mar 31, 2025.

Latest HYPR News

Hyperfine Benefits as FDA Registry Tops 1,200 AI Devices, Spurring Funding Surge — Mar 27, 2026
Hyperfine Raises Price to $590K, Reports Record Q4 Growth and India Approval — Mar 19, 2026
Hyperfine Q4 2025 Forecast at $5.16M Revenue, Price Target Implies 39% Upside — Mar 17, 2026
Hyperfine enrolls first patient in contrast MRI trial, eyes $70.92B point-of-care market — Jan 16, 2026
Hyperfine Enrolls First Patient in Swoop Portable MRI Contrast Agent Feasibility Study — Jan 16, 2026

Recent HYPR Insider Trades

TEISSEYRE THOMAS sold 24.19K (~$29.27K) on Mar 23, 2026.
HALE BRETT sold 24.19K (~$29.27K) on Mar 23, 2026.
TEISSEYRE THOMAS sold 821 (~$912.541) on Feb 13, 2026.

HYPR Analyst Consensus

3 analysts cover HYPR: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $2.17.

Common questions about HYPR

Who owns HYPR stock?: Hedge funds tracked by Rallies that own HYPR include Highbridge Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Hyperfine, Inc. Class A Common Stock.
Does Rallies show 13F holders for HYPR?: Yes. Rallies tracks hedge fund and 13F ownership data for HYPR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is HYPR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HYPR. It does not provide personalized investment advice.